After opening an office in April in Bidart in the Basque Country, the Swiss firm SOPHiA GENETICS, a world leader in data-based medicine, is opening a new R&D centre in Bordeaux, located in the Cité de la Photonique and plans to create 30 jobs.
A startup ranked as one of the 50 smartest companies in the world!
Sophia Genetics, founded in 2011 in Lausanne is consistently recognised in the international rankings.
Specialised in developing algorithms which are used to analyse genomic data, the company was ranked as one of the 50 smartest companies by MIT Review and as one of the 10 most innovative biotech companies in the world by Fast Company magazine.
It is now pinning its hopes on France to strengthen its artificial intelligence platform, by creating centres in Nouvelle Aquitaine, starting with the Bidart centre and followed by the Bordeaux location.
The artificial intelligence technology developed by SOPHIA is used by over 850 hospitals in 72 countries to improve diagnoses and quickly analyse medical data to enhance care for patients with cancer or genetic diseases.
With this new radiomics unit in Bordeaux, the company plans to develop its medical imaging activity using technology developed by Professor Thierry Colin’s team at INRIA.
SOPHiA GENETICS’ acquisition of the Nénuphar software program developed by INRIA, through a transfer carried out by SATT Aquitaine Sciences Transfert, has enabled the firm to incorporate this expertise in numerical modelling in radiology.
Research carried out by Professor Colin, a mathematician and researcher, and his team at INRIA in Bordeaux, was a key factor in the firm’s decision to come to Bordeaux. Thierry Colin, who oversees research on cancer modelling using X-ray images as part of the Nénuphar project, has now joined SOPHIA GENETICS in a secondment position.
The presence of renowned Bordeaux institutions such as the University Hospital and the Bergonié Institute also weighed in Bordeaux’s favour, as did the presence of ENSEIRB, an engineering school that trains future artificial intelligence technicians. With 500 students per year, SOPHiA GENETICS can count on a pool of talent to recruit from.
A staff of ten are currently based at the centre, in the Cité de la Photonique, next to the campus. The firm will continue to recruit engineering, doctoral and sales positions to reach a staff of about thirty over the next three years.
Invest in Bordeaux supported SOPHiA GENETICS’ development by putting Jurgi Camblong, co-founder of the company, into contact with Professor Colin’s team at INRIA.